Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 3/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | CALCA | P06881 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | CRHBP | P24387 | 1/20 | 0.41 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2131491 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL2130537 | 0.99 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL2130250 | 0.99 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL30796336 | 0.99 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL30795097 | 0.99 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL2131351 | 0.98 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL30794990 | 0.98 | SMN1; SMN2 (0.45) | SMN1; SMN2LMNAPOLBTP53MAPT | |
| SCHEMBL30794521 | 0.93 | SRC (0.44) | SMN1; SMN2LMNAPOLBTP53ALDH1A1 | |
| SCHEMBL2129031 | 0.93 | SRC (0.44) | SMN1; SMN2LMNAPOLBTP53ALDH1A1 | |
| SCHEMBL2130990 | 0.93 | RET (0.46) | SMN1; SMN2TP53MAPTCHRM4SCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4584250-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | Biohaven Therapeutics Ltd. (VG) | 2025-07-16 | — | — | EP | disclosed |
| EP-4580679-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | Biohaven Therapeutics Ltd. (VG) | 2025-07-09 | — | — | EP | disclosed |
| WO-2024054811-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024054807-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND TDP-43 MODULATORS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-14 | — | — | WO | disclosed |
| WO-2024050389-A1 | COMBINATION THERAPIES INCLUDING METAL CHANNEL ACTIVATORS AND NMDA RECEPTOR ANTAGONISTS | BIOHAVEN THERAPEUTICS LTD. (VG) | 2024-03-07 | — | — | WO | disclosed |